Comment on: Shams El-Din El-Behiri et al., Hypofractionated versus conventional IMRT in unfavorable intermediate- and high-risk prostate cancer: A phase II comparative study of PSA kinetics, dosimetric and toxicity outcomes, The French Journal of Urology, 2026
